Advertisement


Samuel M. Silver, MD, PhD, and Margaret A. Tempero, MD, on Multidisciplinary Management of Pancreatic Cancer

2015 NCCN Annual Conference

Advertisement

Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discuss drugs developed for hematologic malignancies that have activity in pancreatic cancer, vaccines, neoadjuvant treatment, and the need to focus on activated RAS.



Related Videos

Robert W. Carlson, MD, and John A. Gentile, Jr, on Milestones of NCCN

Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and John A. Gentile, Jr, Chairman, Harborside Press, LLC, discuss the early ...

Lymphoma

Andrew D. Zelenetz, MD, PhD, on Emerging Treatment Options for Lymphomas

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, talks about the revolution in lymphoma treatment, which started with rituximab and continues with obinutuzum...

Samuel M. Silver, MD, PhD, and Al B. Benson III, MD, FACP, FASCO, on 20 Years of Improving Cancer Care Together: A Clinical Perspective

Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Al B. Benson III, MD, FACP, FASCO, of Robert H. Lurie Comprehensive Cance...

Breast Cancer

Robert W. Carlson, MD, and William J. Gradishar, MD, on Optimizing Treatment of HER2-Positive Breast Cancer

Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and William J. Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center of...

Skin Cancer
Symptom Management

Mario E. Lacouture, MD, on Management of Dermatologic Toxicities Associated With Targeted Therapies

Mario E. Lacouture, MD, of Memorial Sloan Kettering Cancer Center, discusses the effect on patients of dermatologic toxicities associated with targeted therapies: their psychosocia...

Advertisement

Advertisement



Advertisement